Report Overview
Alcohol use disorder (AUD), is a chronic condition characterized by an inability to control alcohol consumption despite negative consequences. It involves a physical and psychological dependence on alcohol, where individuals may experience cravings, withdrawal symptoms, and a persistent desire to drink. Medications for Alcohol Use Disorder (AUD) are an important component of treatment, helping individuals manage cravings, reduce alcohol consumption, and maintain sobriety. Currently, commonly used drugs include naltrexone, acamprosate, etc. The global Medications for Alcohol Use Disorder (AUD) market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030. Analytic Insights Hub's' newest research report, the ?Medications for Alcohol Use Disorder (AUD) Industry Forecast? looks at past sales and reviews total world Medications for Alcohol Use Disorder (AUD) sales in 2022, providing a comprehensive analysis by region and market sector of projected Medications for Alcohol Use Disorder (AUD) sales for 2023 through 2029. With Medications for Alcohol Use Disorder (AUD) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Medications for Alcohol Use Disorder (AUD) industry. This Insight Report provides a comprehensive analysis of the global Medications for Alcohol Use Disorder (AUD) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Medications for Alcohol Use Disorder (AUD) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Medications for Alcohol Use Disorder (AUD) market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Medications for Alcohol Use Disorder (AUD) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Medications for Alcohol Use Disorder (AUD). United States market for Medications for Alcohol Use Disorder (AUD) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030. China market for Medications for Alcohol Use Disorder (AUD) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030. Europe market for Medications for Alcohol Use Disorder (AUD) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030. Global key Medications for Alcohol Use Disorder (AUD) players cover Alkermes, Merck KGaA, Lundbeck, Alvogen, Mylan, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023. This report presents a comprehensive overview, market shares, and growth opportunities of Medications for Alcohol Use Disorder (AUD) market by product type, application, key players and key regions and countries. Segmentation by Type: Naltrexone Acamprosate Disulfiram Other Segmentation by Application: Hospital Rehabilitation Institutions Others This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries Segmentation by Type: Naltrexone Acamprosate Disulfiram Other Segmentation by Application: Hospital Rehabilitation Institutions Others This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration. Alkermes Merck KGaA Lundbeck Alvogen Mylan Teva Sun Pharmaceutical Industries Zydus Pharmaceuticals Taj Pharmaceuticals TAGI Pharma Inc. Beijing Wellso Pharmaceutical Co Glenmark Pharmaceuticals Rusan Pharma Ltd